Latest Victory Pharma Inc. Stories
BOSTON, Dec. 27, 2012 /PRNewswire/ -- In the second False Claims Act brought by whistleblowers represented by the Boston law firm of Ellis & Rapacki LLP to have settled in the last eight days, Victory Pharma, Inc. ("Victory") has agreed to pay $12.2 million to the federal and state governments and has entered into a deferred criminal prosecution agreement. The settlement with Victory resolves allegations that, from 2007 to 2009, the pharmaceutical company offered and paid illegal...
In the news release, Victory Pharma Completes Acquisition of Assets of MiddleBrook Pharmaceuticals, issued 03-Aug-2010 by Victory Pharma, Inc. over PR Newswire, the fourth paragraph, second sentence, should include hyperlinks to http://www.victorypharma.com/documents/mbrkreleaserefs08022010.html on the referenced footnotes "1,2,3" and "4" rather than plain text as incorrectly transmitted by PR Newswire. The complete, corrected release follows: Victory Pharma Completes Acquisition of Assets...
SAN DIEGO, Aug. 3 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") today announced that it has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc. (OTCQB: MBRKQ). Through the acquisition, Victory Pharma has expanded its product portfolio with the addition of anti-infective products MOXATAG® and KEFLEX® as well as the PULSYS® drug delivery technology platform. The product additions complement Victory's current products, such as...
SAN DIEGO, Nov. 23 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise. NAPRELAN Dose Card is designed for patients who require relief from mild to moderate pain and inflammation associated with primary dysmenorrhea and acute tendinitis and bursitis. It is also designed for patients suffering from rheumatoid arthritis or osteoarthritis who may be receiving other therapies and need...
SAN DIEGO, July 13 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Victory's lead investigational rug, MGX006. If approved, MGX006 will provide patients and healthcare providers the advantage of a proven antiemetic agent combined with a proprietary formulation ideally suited for the treatment of nausea and vomiting."Acceptance of the MGX006 NDA is a significant...
SAN DIEGO, March 9 /PRNewswire/ -- Victory Pharma, Inc. ("Victory" or "the Company"), a privately held specialty pharmaceutical company, today announced that it has closed on a $45 million equity financing facility led by Essex Woodlands Health Ventures ("Essex"). Ampersand Ventures, an existing investor, also participated in the financing. Proceeds will be used to support future growth initiatives, including product acquisitions. As part of the transaction, Victory announced that Scott...
SAN DIEGO, Jan. 8 /PRNewswire/ -- Victory Pharma, Inc., a privately held specialty pharmaceutical company, today announced that it is launching two additional dosage strengths of Naprelan(R) (naproxen sodium) Controlled-Release Tablets. NAPRELAN is a once-daily, controlled-release formulation of naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of a number of conditions, including osteoarthritis, rheumatoid arthritis and management of mild to...
